BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MM-111: Phase I started

Merrimack began an open-label, dose-escalation, U.S. Phase I trial in about 24 patients to evaluate once-weekly MM-111 in combination with cisplatin, capecitabine and trastuzumab; lapatinib and trastuzumab; or paclitaxel and trastuzumab.

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >